Skip to content
Review Open access

Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Sep 2026 · Drug Design, Development and Therapy · Vol 20 · 0 citations · 222 references
Medicine

TL;DR

Emerging therapeutics through a liver cell-centered framework are summarized, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cell modulators, and precision-delivery technologies.

Abstract

Abstract Metabolic dysfunction-associated steatohepatitis (MASH) is not solely a disorder of hepatocellular lipid accumulation, but a multicellular disease driven by coordinated metabolic stress, sterile inflammation, fibrogenesis, and niche remodeling. Recent therapeutic progress with the provisional approval of resmetirom and semaglutide has validated MASH as a tractable clinical target. However, many experimental agents have shown limited or inconsistent efficacy, particularly for regression of hepatic fibrosis or cirrhosis, reflecting the biological heterogeneity and dynamic cellular architecture of the disease. Distinct from conventional pathway- or drug class-based reviews, we summarize emerging therapeutics through a liver cell-centered framework, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cell modulators, and precision-delivery technologies. We further compare how these interventions reshape pathogenic communication among hepatic and extrahepatic compartments, while emphasizing unresolved challenges in drug target selection, cellular specificity, disease-stage dependency, safety, and patient stratification. This perspective emphasizes the need to move from isolated pathway targeting toward cell- and network-informed therapeutic strategies supported by spatial multi-omics, human-relevant models, and precision delivery.

Read PDF

Similar papers

Review Open access Sep 2026

siRNA therapeutics for metabolic dysfunction-associated Steatohepatitis: Targets, delivery, clinical evidence, and translational challenges

This review critically evaluates target selection, delivery, clinical and preclinical evidence, unsuccessful programs, competing nucleic acid modalities, and combination strategies in metabolic dysfunction-associated steatotic liver disease.

Ya-Nan Guo, Qun-Yan Yao · 0 citations
Review Open access Sep 2026

Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting approximately one-third of the global adult population, acting as the primary driver of cirrhosis and hepatocellular carcinoma. Despite its growing incidence and substantial clinical and soc...

Ming-Yue Zhou, Jin-Hai Huo, Wei Wang et al. · 0 citations
Review Open access Oct 2026

Regenerative failure in metabolic dysfunction-associated steatohepatitis: The entrapped progenitor model and precision repair

A “precision regenerative hepatology” framework integrating spatial omics-guided niche mapping, targeted delivery platforms, and advanced patient-specific preclinical models is presented as a clinically translatable therapeutic roadmap.

Dhruv Gehlot, Swayam Bakriwala, Y. Patel · 0 citations
Review Open access Aug 2026

New therapeutic options for metabolic-associated steatotic liver disease.

An increasing number of patients are being diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). MASLD results from disturbances in hepatic lipid metabolism and is associated with an increased risk of cirrhosis and hepatocellular carcinoma and significant extrahepatic morbidity, including car...

T. Straatmijer, M. Mulder · 0 citations
Review Open access Sep 2026

Targeting gut dysbiosis: a new frontier in MASLD management

This narrative review explores the mechanistic pathways through which an altered gut microbiome contributes to MASLD, by specifically emphasizing intestinal barrier disruption, endotoxemia, altered bile acid metabolism, and SCFA imbalance.

Shweta Sharma, Arun Pachauri, Harsha Nagar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.